RU2125448C1 - Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов - Google Patents

Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов Download PDF

Info

Publication number
RU2125448C1
RU2125448C1 RU94031161A RU94031161A RU2125448C1 RU 2125448 C1 RU2125448 C1 RU 2125448C1 RU 94031161 A RU94031161 A RU 94031161A RU 94031161 A RU94031161 A RU 94031161A RU 2125448 C1 RU2125448 C1 RU 2125448C1
Authority
RU
Russia
Prior art keywords
inhibitor
mao
composition according
absorption
group
Prior art date
Application number
RU94031161A
Other languages
English (en)
Russian (ru)
Other versions
RU94031161A (ru
Inventor
Мадьяр Кальман
Гаал Йожеф
Сираки Иштван
Лендьел Йожеф
Сабо Анна
Мармароши Каталин
Хермец Иштван
Сатмари Иштван
Терек Золтан
Кермеци Петер
Original Assignee
Хиноин Дьедьсер еш Ведьесети Термекек Дьяра РТ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хиноин Дьедьсер еш Ведьесети Термекек Дьяра РТ filed Critical Хиноин Дьедьсер еш Ведьесети Термекек Дьяра РТ
Publication of RU94031161A publication Critical patent/RU94031161A/ru
Application granted granted Critical
Publication of RU2125448C1 publication Critical patent/RU2125448C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU94031161A 1991-12-20 1992-12-18 Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов RU2125448C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU4060/91 1991-12-20
HU914060A HUT63579A (en) 1991-12-20 1991-12-20 Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
PCT/HU1992/000060 WO1993012775A1 (en) 1991-12-20 1992-12-18 Pharmaceutical composition and process for the preparation thereof

Publications (2)

Publication Number Publication Date
RU94031161A RU94031161A (ru) 1996-03-27
RU2125448C1 true RU2125448C1 (ru) 1999-01-27

Family

ID=10966728

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94031161A RU2125448C1 (ru) 1991-12-20 1992-12-18 Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов

Country Status (27)

Country Link
US (1) US5589513A (https=)
EP (1) EP0617615A1 (https=)
JP (1) JPH07502730A (https=)
KR (1) KR940703655A (https=)
AU (1) AU677170B2 (https=)
BG (1) BG98827A (https=)
BR (1) BR9206950A (https=)
CA (1) CA2125776A1 (https=)
CZ (1) CZ147494A3 (https=)
EC (1) ECSP930933A (https=)
EE (1) EE03015B1 (https=)
FI (1) FI942932A7 (https=)
HU (2) HUT63579A (https=)
IL (1) IL104150A (https=)
LT (1) LT3119B (https=)
LV (1) LV10386B (https=)
MY (1) MY111055A (https=)
NO (1) NO942303D0 (https=)
NZ (1) NZ246384A (https=)
PH (1) PH31073A (https=)
PL (1) PL172048B1 (https=)
RO (1) RO115785B1 (https=)
RU (1) RU2125448C1 (https=)
SI (1) SI9200404A (https=)
SK (1) SK74494A3 (https=)
WO (1) WO1993012775A1 (https=)
ZA (1) ZA929883B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2194983C2 (ru) * 2000-06-30 2002-12-20 Научно-исследовательский институт военной медицины Способ оценки нейротоксичности сыворотки крови больных с заболеваниями печени
RU2505528C2 (ru) * 2007-10-26 2014-01-27 Пирамал Имэджинг СА Соединения для применения в визуализации, диагностике и/или лечении заболеваний центральной нервной системы или опухолей

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
DE4432610C1 (de) * 1994-09-13 1996-02-01 Knoll Ag Verfahren zur Herstellung von Selegilin-Hydrochlorid
CA2212412A1 (en) 1995-02-10 1996-08-15 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
JP4499208B2 (ja) * 1998-10-29 2010-07-07 株式会社フジモト・コーポレーション 新規な光学活性アミノペンタン誘導体
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
HUP9902482A2 (hu) * 1999-07-22 2002-04-29 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. P-fluoro-selegilin alkalmazása neuroprotektív gyógyszerkészítmények előállítására
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
DE102009045056A1 (de) * 2009-09-28 2011-03-31 Henkel Ag & Co. Kgaa Fleckenvorbehandlungsmittel
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
AU2019308326B2 (en) 2018-07-20 2025-07-31 Lipocine Inc. Liver disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960797A (en) * 1984-05-31 1990-10-02 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. N-2[(4-fluoro-phenyl)-1-methyl]-2-ethyl-N-methyl-N-propynyl amine and the method of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1227447B (de) * 1962-03-30 1966-10-27 Chinoin Gyogyszer Es Vegyeszet Verfahren zur Herstellung von Phenylisopropylaminen
HU193662B (en) * 1983-12-20 1987-11-30 Chinoin Gyogyszer Es Vegyeszet Process for producing synergetic pharmaceutical composition of antidepressive aktivity
EP0241809B1 (de) * 1986-04-16 1990-08-08 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Amantadin und Selegilin
HU207280B (en) * 1986-09-25 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
CA2037178A1 (en) * 1990-02-28 1991-08-29 Albert Walter Brzeczko Deprenyl/l-dopa/carbidopa pharmaceutical composition
GB9011767D0 (en) * 1990-05-25 1990-07-18 Britannia Pharmaceuticals Ltd Pharmaceutical compositions
US5169868A (en) * 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
HU209605B (en) * 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960797A (en) * 1984-05-31 1990-10-02 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. N-2[(4-fluoro-phenyl)-1-methyl]-2-ethyl-N-methyl-N-propynyl amine and the method of use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2194983C2 (ru) * 2000-06-30 2002-12-20 Научно-исследовательский институт военной медицины Способ оценки нейротоксичности сыворотки крови больных с заболеваниями печени
RU2505528C2 (ru) * 2007-10-26 2014-01-27 Пирамал Имэджинг СА Соединения для применения в визуализации, диагностике и/или лечении заболеваний центральной нервной системы или опухолей

Also Published As

Publication number Publication date
FI942932L (fi) 1994-06-17
RO115785B1 (ro) 2000-06-30
WO1993012775A1 (en) 1993-07-08
JPH07502730A (ja) 1995-03-23
IL104150A (en) 1997-11-20
BR9206950A (pt) 1995-11-28
FI942932A0 (fi) 1994-06-17
SI9200404A (en) 1993-06-30
LT3119B (en) 1994-12-27
LV10386B (en) 1995-12-20
KR940703655A (ko) 1994-12-12
PH31073A (en) 1998-02-05
BG98827A (bg) 1995-06-30
HUT63579A (en) 1993-09-28
CZ147494A3 (en) 1995-01-18
FI942932A7 (fi) 1994-06-17
LV10386A (lv) 1995-02-20
NZ246384A (en) 1996-02-27
EP0617615A1 (en) 1994-10-05
ZA929883B (en) 1994-05-16
SK74494A3 (en) 1995-01-12
MY111055A (en) 1999-08-30
LTIP249A (en) 1994-07-15
HU211478A9 (en) 1995-11-28
ECSP930933A (es) 1994-04-20
PL172048B1 (pl) 1997-07-31
AU3265293A (en) 1993-07-28
NO942303L (https=) 1994-08-17
EE03015B1 (et) 1997-08-15
HU914060D0 (en) 1992-03-30
AU677170B2 (en) 1997-04-17
US5589513A (en) 1996-12-31
CA2125776A1 (en) 1993-07-08
NO942303D0 (no) 1994-06-17

Similar Documents

Publication Publication Date Title
RU2125448C1 (ru) Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов
AU2018201436B2 (en) New therapeutic approaches for treating Parkinson's disease
US9259418B2 (en) Pharmaceutical compositions for treatment of Parkinson's disease
CN107106521B (zh) 用于治疗帕金森病的治疗方法
JPH02500596A (ja) 医薬組成物
HK1203417B (en) New therapeutic approaches for treating parkinson's disease